elvn-002
elvn-002: sourced relationships with 1 company · 2 clinical trials tracked.
elvn-002 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could elvn-002 → ELVN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Enliven Therapeutics, Inc. (ELVN) HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Breast… | Phase 1 |
Clinical Trial Registry Records (2)
A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer
Primary endpoint: Incidence of dose limiting toxicities (DLTs; Phase 1a only)
A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer
Primary endpoint: Incidence of dose limiting toxicities in Phase 1a monotherapy
Frequently asked questions
Which companies have sourced relationships with elvn-002?
elvn-002 has dated SEC/FDA relationship records for Enliven Therapeutics, Inc..
How many clinical trials involve elvn-002?
BioSniper tracks 2 clinical trials involving elvn-002.